A Comparative Analysis of Speech Perception Between Cochlear Implant Patients and DFNB9 Patients Receiving Gene Therapy
This study compares how well people with hearing loss can understand speech after receiving either a cochlear implant (a device that helps hearing) or gene therapy treatment. Researchers will measure different aspects of hearing ability to see how effective gene therapy is as a treatment option for people born deaf due to DFNB9 genetic mutations.
Key Objective: The trial evaluates whether gene therapy can restore speech perception in patients with DFNB9-related congenital deafness and how it compares to cochlear implant outcomes.
Who to Consider: People with congenital hearing loss caused by DFNB9 mutations or those considering cochlear implant treatment who want to understand how newer gene therapy approaches compare.
Trial Parameters
Brief Summary
This cohort study aims to explore the trends and differences in multidimensional perceptual levels of patients after cochlear implants or gene therapy, as well as to comprehensively assess the efficacy of gene therapy for congenital deafness, thus providing a reference for making a well-rounded postoperative rehabilitation protocol for gene therapy patients.
Eligibility Criteria
Inclusion Criteria: * Patients with congenital hearing loss with hearing thresholds ≥65 dB receive either gene therapy (previously received gene therapy and standardized postoperative rehabilitation and follow-up or plan to receive gene therapy), or cochlear implant surgery. Healthy participants with bilateral hearing thresholds within the normal range (≤20 dB), generally matched to the gene therapy group and the cochlear implant group by age and sex. * Age ≥ 6 months old, regardless of gender. * Mandarin Chinese as the native language. * Participants and their guardians must provide informed consent before the trial, voluntarily sign a written consent form, and commit to follow-up at specified time points. * Capable of effective communication with researchers under the guardian's assistance and willing to cooperate and comply with the researchers' requirements. * The participant's guardians should have a correct understanding of the trial and appropriate expectations regarding potenti